Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299731 | 1.00 | SLC6A3 (0.35) | SLC6A3USP30SLC7A5MEN1KMT2A | |
| SCHEMBL6207126 | 0.86 | HDAC1 (0.39) | SLC7A5MEN1KMT2A | |
| SCHEMBL6294115 | 0.86 | SLC6A3 (0.39) | SLC6A3USP30MEN1KMT2A | |
| SCHEMBL5846260 | 0.85 | KMT2A (0.40) | MEN1KMT2A | |
| SCHEMBL6295154 | 0.81 | SLC6A3 (0.34) | SLC6A3USP30MEN1KMT2A | |
| SCHEMBL642839 | 0.80 | SMN1; SMN2 (0.41) | SLC7A5MEN1KMT2ATRPM8 | |
| SCHEMBL9382586 | 0.80 | SMN1; SMN2 (0.41) | SLC7A5MEN1KMT2ATRPM8 | |
| SCHEMBL27629079 | 0.78 | AAK1 (0.32) | USP30SLC7A5 | |
| SCHEMBL1521915 | 0.77 | USP30 (0.34) | SLC6A3USP30MEN1KMT2A | |
| SCHEMBL10521312 | 0.77 | NR1H2 (0.34) | USP30SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962934-B2 | Substituted amino carboxamides for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030166580-A1 | Substituted amino carboxamides for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166580-A1 | Substituted amino carboxamides for the treatment of alzheimer's disease | BACE1, BACE2, APP | SLC6A3 3065/4885USP30 1716/4885SLC7A5 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.